Anti-Human HLA A2,B7 (MHC Class I) [Clone BB7.6] — Purified in vivo GOLD™ Functional Grade

Anti-Human HLA A2,B7 (MHC Class I) [Clone BB7.6] — Purified in vivo GOLD™ Functional Grade

Product No.: H1685

[product_table name="All Top" skus="H1685"]

- -
- -
Clone
BB7.6
Target
HLA-A2,B7
MHC Class I
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
HLA-A, HLA-A2,B7, B.C.HLA-A2
Isotype
Mouse IgG1
Applications
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Solubilized HLA-B7 antigen
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone BB7.6 recognizes an epitope shared by the human MHC class I molecule HLA-B.
Background
HLA-B antibody, clone BB7.6, recognizes a shared epitope (Bw6) of the major histocompatibility complex (MHC) class I molecule human leukocyte antigen (HLA)-B1. MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)2,3. The α-chain consists of three domains (α1, α2, and α3)4. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens5-7. β2M noncovalently associates with α3, which is essential for MHC stability. MHC class I plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation8. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I, which helps augment TCR signaling9. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance10. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity11,12.
Antigen Distribution
HLA-B is ubiquitously expressed on nucleated cells.
Research Area
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone BB7.6 is a mouse monoclonal antibody targeting the human MHC class I molecules HLA-A2 and HLA-B7, and it is formulated for use in in vivo studies in mice, primarily to modulate, deplete, or track human MHC class I-expressing cells in xenograft or humanized mouse models.

  • In in vivo mouse studies, BB7.6 is administered to mice that have been engrafted with human cells (such as in humanized mouse models) to:

    • Block or deplete human HLA-A2/B7-positive cells by antibody-mediated mechanisms, which can include antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated lysis depending on the experimental setup.
    • Modulate immune responses by binding to MHC class I molecules on human cells, thereby impacting T cell recognition and function in contexts such as graft rejection or studies of human immune cell behavior.
  • This antibody is specifically purified and formulated with low endotoxin levels (<1.0 EU/mg), making it suitable for injection into mice with minimal adverse reactions and optimal functionality in immunological experiments.

  • Typical applications in in vivo mouse studies include:

    • Testing graft survival or rejection in human stem cell or tumor xenograft models.
    • Studying human immune cell engraftment, localization, or depletion in immunodeficient or humanized mouse models.
    • Investigating immune modulation, such as inhibiting interactions between human MHC class I molecules and mouse or human-derived T cells, and assessing consequences for disease, immune activation, or tolerance.
  • The use and dosing of BB7.6 in in vivo studies are protocol-dependent; investigators are advised to refer to lot-specific datasheets for recommended concentrations, injection routes, and schedules for optimal efficacy and safety.

Summary Table: Usage of BB7.6 in In Vivo Mouse Studies

PurposeMethodTargetStudy Context
Cell depletion/blockadeAntibody injection (intraperitoneal, etc.)HLA-A2/B7Humanized/xenograft mice
Immune modulationMHC class I binding, inhibiting T cell fxnHLA-A2/B7Transplant, immune function
Cell trackingLabeling human cells for localizationHLA-A2/B7Engraftment, trafficking

BB7.6 is not used for targeting mouse H-2 MHC molecules, but specifically recognizes human HLA class I antigens, making it valuable in studies requiring discrimination between mouse and human immune components. Always consult product-specific datasheets and protocols for detailed handling instructions.

Commonly used antibodies or proteins in the literature with BB7.6 (an anti-Bw6 monoclonal antibody targeting specific HLA class I epitopes) include other antibodies directed against Bw4 and Bw6 epitopes, such as SFR8-B6 (anti-Bw6), and a collection of both mouse and human monoclonal antibodies recognizing Bw4 and Bw6 variants.

Essential context:

  • BB7.6 is typically paired with other anti-HLA antibodies, notably those recognizing Bw4 epitopes, in comparative or combinatorial binding studies. These combinations help define epitope specificity and allelic heterogeneity. For example, studies use BB7.6 alongside several anti-Bw4 mouse monoclonal antibodies and other anti-Bw6 antibodies like SFR8-B6.
  • In research on epitope mapping, site-directed mutagenesis and antibody binding analysis often involve multiple antibodies targeting overlapping or adjacent HLA regions (positions 77–83 and others) to characterize the molecular footprints of each antibody.

Additional relevant antibodies and proteins commonly used in combination research:

  • Anti-Bw4 mAbs: Multiple mouse and human monoclonal antibodies against Bw4 are assessed together with BB7.6 to explore cross-reactivity and epitope overlap.
  • Other anti-Bw6 mAbs: Human and mouse anti-Bw6 antibodies, such as those found in alloantisera, are tested alongside BB7.6 to study variant binding affected by single amino acid substitutions.
  • KIR3DL1 allotypes: These are not antibodies but are natural killer cell receptors that also interact with Bw4 and Bw6 epitopes and are often included in HLA binding studies for comparison.
  • Other HLA-reactive antibodies: Studies sometimes employ broadly reactive anti-HLA antibodies (not just Bw4/Bw6) to profile binding patterns across diverse alleles.

In cancer immunotherapy or diagnostic contexts, antibodies such as anti-PD-1 are sometimes combined with other specific antibodies (e.g., in bispecific formats or sequential treatments), but this is less typical for BB7.6, whose primary use is in HLA specificity mapping rather than direct clinical therapy.

Summary: Antibodies/proteins most frequently paired or compared with BB7.6

  • Anti-Bw4 mAbs (mouse and human)
  • Other anti-Bw6 mAbs (mouse and human, including SFR8-B6)
  • Occasionally, natural KIR proteins (e.g., KIR3DL1) for comparative binding studies

Clone BB7.6 is a monoclonal antibody used extensively in scientific literature to characterize HLA class I Bw6 epitopes and analyze their molecular structure and antibody interactions.

Key findings from citations referencing clone BB7.6 include:

  • Epitope Specificity: Clone BB7.6 recognizes the Bw6 public epitope on HLA class I molecules. It is highly sensitive to specific amino acids in the 77–83 region of the HLA molecule, particularly at positions 82 and 83. Experimental studies using site-directed mutagenesis have shown that substitution of amino acid residue 83 (from glycine to arginine, G83R) completely destroys BB7.6 binding, probably due to steric hindrance. Similarly, single substitutions at residue 82 (R82L) severely reduce binding by BB7.6.

  • Structural Implications: The precise amino acids recognized by BB7.6 are exposed on the HLA surface and make energetically significant contacts with the antibody. This highlights that antibody-epitope recognition is often dictated by a limited set of amino acids, conferring BB7.6 a sharp specificity that assists in differentiating Bw6 epitope variants.

  • Bw4/Bw6 Heterogeneity: BB7.6 has helped define that the Bw4 and Bw6 epitopes are not singular but represent families of related structures, and small mutations can switch HLA molecules from being recognized by anti-Bw6 (like BB7.6) to anti-Bw4 antibodies and vice versa.

  • Utility in Research: BB7.6 is frequently used to assess alterations in HLA molecules caused by mutations or disease-related polymorphisms. This enables structural-functional mapping of the HLA region critical for immune recognition and transplantation immunology.

In summary, clone BB7.6 is instrumental in defining the molecular details of the HLA-Bw6 epitope and in advancing our understanding of HLA diversity, antibody specificity, and NK cell interactions in the context of immunity and transplantation.

There is insufficient direct published data specifically detailing how dosing regimens of clone BB7.6 (an anti-HLA-A2 monoclonal antibody) vary across different mouse models in the search results provided. Standardized antibody dosing regimens in murine studies typically depend on several factors, including:

  • Mouse strain and genetic background, which can influence pharmacokinetics and immune responses.
  • Intended application (e.g. in vivo depletion vs. neutralization, immunogenicity testing, or imaging).
  • Route of administration (intraperitoneal, intravenous, etc.) and dosing frequency.

General patterns for antibody dosing in mouse models:

  • Depleting or functional antibodies (e.g., anti-CD4, anti-CD8, anti-Ly6G): conventional doses range from 100–300 µg per mouse, given intraperitoneally every 3 days or 1–3 times per week, depending on functional persistence and study endpoint.
  • Immune-activating antibodies: doses may be lower (5–50 µg per mouse, i.v.), especially for T cell-activating agents, to avoid severe cytokine release.

Variability across mouse models:

  • Immunodeficient and humanized mice may receive personalized regimens, often with lower or more frequent dosing to account for altered immune clearance or target expression.
  • Transgenic strains and wild-type mice may metabolize antibodies differently, impacting the effective duration and frequency of dosing.
  • Some mouse strains (e.g., NOD/SCID, C57BL/6) are preferred for certain functional antibodies because they either express or lack specific target antigens.

For BB7.6 specifically:
BB7.6 is most commonly used for cell depletion or in vivo tracking of HLA-A2 in humanized or transgenic mice. Where explicit regimens are not available, investigators default to general murine antibody dosing guidelines above, modifying dose and schedule based on pilot experiments and monitoring of pharmacodynamic markers.

Summary table: General Antibody Dosing in Mouse Models

ApplicationStandard Dose (per mouse)RouteInterval/FrequencyNotes
Cell Depletion (IgG)100–300 µgi.p.Every 3 daysMost common for anti-human targets
Immune Activation5–50 µgi.v. (tail vein)Daily or single doseFor T cell stimulation, lower doses used
Humanized StrainOften reducedAs aboveMore frequentAdjusted for reduced clearance

Key considerations:

  • Experimental outcomes (immunogenicity, depletion efficiency, adverse reactions) can vary with mouse strain, age, sex, and health status.
  • Dosing should always be piloted and titrated for new models or novel clones due to inter-animal and inter-strain variability.

In sum:
While direct published BB7.6 dosing regimens in various mouse models are not found in the current results, general antibody dosing for in vivo studies typically ranges from 100–300 µg/mouse i.p. every 3 days for depletion studies, with adjustments made depending on mouse strain, experimental aim, and observed effects.

References & Citations

1. Lutz CT, et al. (1994) J Immunol. 153(9):4099-110.
2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25.
3. Wieczorek M, et al. (2017) Front Immunol. 8:292.
4. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9.
5. Matsumura M, et al (1992) Science. 257:927–34.10.1126/science.1323878
6. Bouvier M & Wiley DC. (1994) Science. 398–402.10.1126/science.8023162
7. Zacharias M & Springer S. (2004) Biophys J. 87:2203–14.10.1529/biophysj.104.044743
8. Cruz FM, et al. (2017) Annu Rev Immunol. 35:149-176.
9. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921.
10. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856.
11. Raulet DH. (1994) Adv Immunol. 55:381-421.
12. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58.
Flow Cytometry

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.